Walgreens should continue to benefit from drug price inflation and growth in its pharmacy services. Its healthcare business, which offers primary care offerings, has done well in the recent quarters, a trend expected to continue. The company's international business, including Boots UK and Germany wholesale, will likely see slight growth. On the flip side, retail sales should see a decline amid a challenging macro environment, with high inflation weighing on consumer sentiment.